MedTrace Logo

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

NCT06050707 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-03-06

No results posted yet for this study

Summary

The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.

Conditions

  • Anal Squamous Cell Carcinoma

Interventions

RADIATION

Radiotherapy - Low risk group

20 fractions completed in 4 weeks

RADIATION

Radiotherapy - Standard risk group

25 fractions completed in 5 weeks

RADIATION

Radiotherapy - Intermediate risk group

30 fractions completed in 6 weeks

RADIATION

Radiotherapy - High risk group

35 fractions completed in 7 weeks

Sponsors & Collaborators

  • Medical College of Wisconsin

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-29
Primary Completion
2028-09-01
Completion
2028-09-01

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06050707 on ClinicalTrials.gov